Biolinq develops a wearable biosensor platform that is capable of measuring blood level information.
Biolinq develops a wearable biosensor platform that is capable of measuring blood level information. Under the leadership of Jared Tangney and Josh Windmiller, Biolinq is redefining how biomedical innovations can be imagined and commercialized. While conducting his post-doctoral research at the University of California, San Diego in the laboratory for NanoBioElectronics, Josh saw the potential to bring nanotechnology to the medical world. Combining forces with Jared, a Ph.D. in Biomedical Engineering, the two saw the opportunity to bring their minimally-invasive technology to the diabetes space. Finally, people with diabetes will have a better CGM experience that is not only more affordable but also pain-free.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Nov 2, 2021 | Series B | $100M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Global Health Funds | — | Series B |